Elsevier Journal Maturitas Publishes Position Statement on Breast Cancer Screening
Amsterdam, September 17,
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of a position statement by the European Menopause and Andropause Society (EMAS) in the journal Maturitas on the topic of breast cancer screening.
Breast cancer is the most prevalent cancer in women, with slightly more than ten percent developing the disease in Western countries. Mammography screening is a well-established method to detect breast cancer. However there are concerns about over diagnosis with population-based screening programmes. Some tumors grow so slowly that they will not threaten the health of women during their lifetime. The women will die from another cause and thus it is argued that these tumors should not have been treated. Treatments can be invasive and painful, have major side-effects, especially in those with significant co-morbidities. While this is easy from an epidemiological standpoint, it is a dilemma for the treating physician dealing with individual women. It is virtually impossible to make the diagnosis of breast cancer and to predict the future behavior of that tumor. Thus individualization is proposed so that women may be categorized into 'low to moderate' and 'high' risk based on familial risk and the first screening mammogram so that further screening can be tailored.
These and other recommendations presented in EMAS' position statement are published in the article, "EMAS Position statement: Individualized breast cancer screening versus population-based mammography screening programmes" by Herman Depypere, Joelle Desreux, Faustino R. Pérez-López, Iuliana Ceausu, C. Tamer Erel, Irene Lambrinoudaki, Karin Schenck-Gustafsson, Yvonne T. van der Schouw, Tommaso Simoncini, Florence Tremollieres and Margaret Rees (DOI: 10.1016/j.maturitas.2014.09.002) and is available online on ScienceDirect.
Notes for editors
Copies of this paper are available to credentialed journalists upon request; please contact Elsevier's Newsroom at email@example.com or +31 20 4853564
About European Menopause and Andropause Society (EMAS)
EMAS promotes the study of midlife health through its journal, congresses, schools and website and encourages the exchange of research and professional experience between members.
Using a range of activities and through its affiliates, EMAS aims to guarantee and provide the same standard of education and information throughout Europe on midlife health in both genders. Recognizing the issues arising from increased longevity the society also provides articles, patient information, web resources, and referrals for healthcare providers in the field and keeps its members up-to-date. For more information go to: http://www.emas-online.org
Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond, publishing original research, reviews, consensus statements and guidelines. The scope encompasses all aspects of postreproductive health in both genders ranging from basic science to health and social care. http://www.maturitas.org/
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
+31 20 485 3323